Skip to main content

Advertisement

SpringerLink
Log in

Immune thrombocytopenic purpura: Historical perspective, current status, recent advances and future directions

  • Review Article
  • Published:
Indian Pediatrics Aims and scope Submit manuscript

Abstract

Immune thrombocytopenic purpura (ITP) has witnessed many changes and updates over the past decade. The definitions of disease subtypes, course and response to treatment have all been standardized recently. Consequent to the lack of an international consensus management guideline, wide variations exist in treatment practice. This is now being addressed to an extent by the much awaited ITP International Working Group 2010 recommendations. The pathophysiologic mechanisms have been unfolded at cellular, molecular and humoral levels. As a result, many recent advances have taken place in the management of this disorder. This review revisits the history of evolution of ITP, summarizes the current recommendations for management and lists the recent advances and future prospects in this field.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an International Working Group. Blood. 2009;113:2386–2393.

    Article  PubMed  CAS  Google Scholar 

  2. Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol. 2010;85:174–180.

    Article  PubMed  Google Scholar 

  3. Werlhof PG. Opera Omnia. Hanover: Helwing, 1775: 748. In: Major RH, editor. Classic Descriptions of Disease. 3rd ed. Springfield, IL: CC Thomas, 1965.

    Google Scholar 

  4. Osler W. An account of certain organisms occurring in the liquor sanguinis. Proc R Soc Med London. 1874;22: 391–399.

    Article  Google Scholar 

  5. Stasi R, Newland AC. ITP: a historical perspective. Br J Haematol. 2011;153:437–450.

    Article  PubMed  Google Scholar 

  6. Harrington WJ, Minnich V, Hollingsworth JW, Moore CV. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med. 1951;38:1–10.

    PubMed  CAS  Google Scholar 

  7. Wintrobe MM, Cartwright GE, Palmer JG, Kuhns WJ, Samuels LT. Effect of corticotrophin and cortisone on the blood in various disorders in man. Arch Int Med. 1951;88:310–336.

    Article  CAS  Google Scholar 

  8. Imbach P, d’Apuzzo V, Hirt A, Rossi E, Vest M, Barandun S, et al. High-dose intravenous gamma globulin for idiopathic thromboctyopenic purpura in childhood. Lancet. 1981;1:1228–1231.

    Article  PubMed  CAS  Google Scholar 

  9. Bussel, JB, Graziano JN, Kimberly RP, Pahwa S, Aledort LM. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood. 1991;77:1884–1893.

    PubMed  CAS  Google Scholar 

  10. Saleh MN, Gutheil J, Moore M, Bunch PW, Butler J, Kunkel L, et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol. 2000;27:99–103.

    PubMed  CAS  Google Scholar 

  11. Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001;114:891–898.

    Article  PubMed  CAS  Google Scholar 

  12. Imbach P, Crowther M. Thrombopoietin receptor agonists for primary immune thrombocytopenia. N Engl J Med. 2011;365:734–741.

    Article  PubMed  CAS  Google Scholar 

  13. Anoop P. Decision to perform bone marrow aspiration in immune thrombocytopenic purpura must be based on evidence. Pediatr Hematol Oncol. 2008;25:91–92.

    Article  PubMed  CAS  Google Scholar 

  14. Nugent D, McMillan R, Nichol JL, Slichter SJ. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol. 2009;146:585–596.

    Article  PubMed  CAS  Google Scholar 

  15. De Mattia D, Del Vecchio GC, Russo G, De Santis A, Ramenghi U, Notarangelo L, et al; AIEOP-ITP Study Group. Management of chronic childhood immune thrombocytopenic purpura: AIEOP Consensus Guidelines. Acta Haematol. 2010;123:96–109.

    Article  PubMed  Google Scholar 

  16. Blanchette V. Childhood chronic immune thrombocytopenic purpura (ITP). Blood Rev. 2002;16:23–26.

    Article  PubMed  CAS  Google Scholar 

  17. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168–186.

    Article  PubMed  CAS  Google Scholar 

  18. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117:4190–4207.

    Article  PubMed  CAS  Google Scholar 

  19. Imbach P, Kuhne T, Muller D, Berchtold W, Zimmerman S, Elalfy M, et al. Childhood ITP: 12 months follow-up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS). Pediatr Blood Cancer. 2006;46:351–356.

    Article  PubMed  CAS  Google Scholar 

  20. Hilgartner MW, Lanzkowsky P, Smith CH. The use of azathioprine in refractory idiopathic thrombocytopenic purpura in children. Acta Paediatr Scand. 1970;59:409–415.

    Article  PubMed  CAS  Google Scholar 

  21. Choudhary DR, Naithani R, Mahapatra M, Kumar R, Mishra P, Saxena R. Efficacy of cyclosporine as a single agent therapy in chronic idiopathic thrombocytopenic purpura. Haematologica. 2008;93:e61–e63.

    Article  PubMed  CAS  Google Scholar 

  22. Hou M, Peng J, Shi Y, Zhang C, Qin P, Zhao C, et al. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol. 2003;70:353–357.

    Article  PubMed  CAS  Google Scholar 

  23. Damodar S, Viswabandya A, George B, Mathews V, Chandy M, Srivastava A. Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults: a report on 90 patients. Eur J Haematol. 2005;75:328–331.

    Article  PubMed  CAS  Google Scholar 

  24. Marwaha RK, Singh RP, Garewal G, Marwaha N, Prakash D, Sarode R. Danazol therapy in immune thrombocytopenic purpura. Pediatr Hematol Oncol. 1990;7:193–198.

    Article  PubMed  CAS  Google Scholar 

  25. Minkov M. Critical issues concerning splenectomy for chronic idiopathic thrombocytopenic purpura in childhood. Pediatr Blood Cancer. 2006;47:734–736.

    Article  PubMed  Google Scholar 

  26. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88:3–40.

    PubMed  CAS  Google Scholar 

  27. Infectious Diseases and Immunization Committee, Canadian Paediatric Society. Prevention and therapy of bacterial infections for children with asplenia or hyposplenia. Paediatr Child Health. 1999;4:417–431.

    Google Scholar 

  28. Kiefel V, Santoso S, Weisheit M, Mueller-Eckhardt C. Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood. 1987;70:1722–1726.

    PubMed  CAS  Google Scholar 

  29. Woods Jr VL, Oh EH, Mason D, McMillan R. Autoantibodies against the platelet glycoprotein IIb/IIIa complex in patients with chronic ITP. Blood. 1984;63:368–375.

    PubMed  Google Scholar 

  30. Houwerzijl EJ, Blom NR, van der Want JJ, Esselink MT, Koornstra JJ, Smit JW, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood. 2004;103:500–506.

    Article  PubMed  CAS  Google Scholar 

  31. Olsson B, Andersson PO, Jernas M, Jacobsson S, Carlsson B, Carlsson LM, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nature Med. 2003;9:1123–1124.

    Article  PubMed  CAS  Google Scholar 

  32. Yu J, Heck S, Patel V, Levan J, Yu Y, Bussel JB, et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood. 2008;112:1325–1328.

    Article  PubMed  CAS  Google Scholar 

  33. Kuter DJ, Gernsheimer TB. Thrombopoietin and platelet production in chronic immune thrombocytopenia. Hematol Oncol Clin North Am. 2009;23:1193–1211.

    Article  PubMed  Google Scholar 

  34. Patel VL, Schwartz J, Bussel JB. The effect of anti-CD40 ligand in immune thrombocytopenic purpura. Br J Haematol. 2008;141:545–548.

    Article  PubMed  CAS  Google Scholar 

  35. Bussel JB, Buchanan GR, Nugent DJ, Gnarra DJ, Bomgaars LR, Blanchette VS, et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood. 2011;118:28–36.

    Article  PubMed  CAS  Google Scholar 

  36. Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:641–648.

    Article  PubMed  CAS  Google Scholar 

  37. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb, B et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357:2237–2247.

    Article  PubMed  CAS  Google Scholar 

  38. Salama A, Rieke M, Kiesewetter H, von Depka M. Experiences with recombinant FVIIa in the emergency treatment of patients with autoimmune thrombocytopenia: a review of the literature. Ann Hematol. 2009;88:11–15.

    Article  PubMed  CAS  Google Scholar 

  39. Emmerich F, Bal G, Barakat A, Milz J, Muhle C, Martinez-Gamboa L, et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol. 2007;136: 309–314.

    Article  PubMed  CAS  Google Scholar 

  40. Li X, Hou M. Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008;13:237–254.

    Article  PubMed  Google Scholar 

  41. Stasi R. Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura. Curr Opin Mol Ther. 2010;12:734–740.

    PubMed  CAS  Google Scholar 

  42. Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood. 2009;113:3154–3160.

    Article  PubMed  CAS  Google Scholar 

  43. Sandoval C, Visintainer P, Ozkaynak MF, Tugal O, Jayabose S. Clinical features and treatment outcomes of 79 infants with immune thrombocytopenic purpura. Pediatr Blood Cancer. 2004;42:109–112.

    Article  PubMed  Google Scholar 

  44. Naithani R, Kumar R, Mahapatra M, Agrawal N, Pati HP, Choudhry VP. Is it safe to avoid bone marrow examination in suspected ITP? Pediatr Hematol Oncol. 2007;24:205–207.

    Article  PubMed  Google Scholar 

  45. Anoop P. Variations in the treatment threshold for immune thrombocytopenic purpura. Pediatr Blood Cancer. 2009;52:429–431.

    Article  PubMed  Google Scholar 

  46. British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120:574–596.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric Hemato-Oncology, Great Ormond Street Hospital for Children, London, UK

    P. Anoop

  2. Department of Pediatric Hemato-Oncology, Apollo Hospital, Bannerghatta Road, Bangalore, 560 076, India

    P. Anoop

Authors
  1. P. Anoop
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Anoop.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Anoop, P. Immune thrombocytopenic purpura: Historical perspective, current status, recent advances and future directions. Indian Pediatr 49, 811–818 (2012). https://doi.org/10.1007/s13312-012-0195-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13312-012-0195-1

Key words

Search

Navigation